- Home
- LPTX vs GF Comparison
LPTX vs GF Comparison
Compare LPTX & GF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- GF
- Stock Information
- Founded
- LPTX 2011
- GF 1990
- Country
- LPTX United States
- GF Germany
- Employees
- LPTX N/A
- GF N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- GF Investment Managers
- Sector
- LPTX Health Care
- GF Finance
- Exchange
- LPTX Nasdaq
- GF Nasdaq
- Market Cap
- LPTX 119.6M
- GF 126.8M
- IPO Year
- LPTX N/A
- GF N/A
- Fundamental
- Price
- LPTX $0.48
- GF $8.82
- Analyst Decision
- LPTX Buy
- GF
- Analyst Count
- LPTX 3
- GF 0
- Target Price
- LPTX $8.50
- GF N/A
- AVG Volume (30 Days)
- LPTX 1.5M
- GF 28.1K
- Earning Date
- LPTX 03-17-2025
- GF 01-01-0001
- Dividend Yield
- LPTX N/A
- GF 0.82%
- EPS Growth
- LPTX N/A
- GF N/A
- EPS
- LPTX N/A
- GF N/A
- Revenue
- LPTX N/A
- GF N/A
- Revenue This Year
- LPTX N/A
- GF N/A
- Revenue Next Year
- LPTX N/A
- GF N/A
- P/E Ratio
- LPTX N/A
- GF N/A
- Revenue Growth
- LPTX N/A
- GF N/A
- 52 Week Low
- LPTX $0.47
- GF $7.38
- 52 Week High
- LPTX $4.79
- GF $9.41
- Technical
- Relative Strength Index (RSI)
- LPTX 19.00
- GF 67.31
- Support Level
- LPTX $0.47
- GF $8.81
- Resistance Level
- LPTX $0.53
- GF $8.99
- Average True Range (ATR)
- LPTX 0.04
- GF 0.10
- MACD
- LPTX 0.07
- GF 0.03
- Stochastic Oscillator
- LPTX 7.42
- GF 77.33
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a United States-based non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.